



THE MODERN PROBLEMS OF CLINICAL PHARMACOLOGY

Teacher of Termez branch of Tashkent State Medical University

Murtazayeva Khadicha Nuriddinovna

Students of Termez branch of Tashkent State Medical University

Anvarov Abbos Abduhamid ugli

Alisherov Ruzimurod Shodibek ugli

<https://doi.org/10.5281/zenodo.20143527>

Abstract: This article provides a broader coverage of the modern problems of clinical pharmacology and their role in medical practice. It analyzes the effectiveness, safety, and side effects of drugs, as well as the issues of drug–drug interactions. The increasing antibiotic resistance, the growing incidence of polypharmacy, and the necessity of an individual approach to patients are considered important issues.

At the same time, the difficulties in the development and clinical testing of new drugs and the role of modern digital technologies in clinical pharmacology are discussed. In particular, the importance of improving pharmacovigilance systems, strengthening the quality control of medicinal products, and preventing counterfeit drugs is emphasized. It is also noted that the implementation of scientific approaches is essential to ensure patient safety and improve treatment effectiveness.

Keywords: Clinical pharmacology, drugs, side effects, drug interactions, antibiotic resistance, polypharmacy, individual approach, clinical trials, counterfeit drugs, digital pharmacology.

Introduction

Clinical pharmacology is considered one of the most important and rapidly developing fields of modern medicine. It studies the effects of drugs on the human body, their effectiveness and safety, and ensures the correct selection and use of medicines in clinical practice. In recent years, due to the rapid development of the pharmaceutical industry, the number of new drugs has been increasing, which has created new tasks and problems for clinical pharmacology.

Currently, side effects of drugs, drug interactions, increasing antibiotic resistance, and the necessity of an individual approach to patients remain among the most urgent issues. In addition, polypharmacy, counterfeit drugs, and difficulties in clinical testing of new drugs are also considered important problems of clinical pharmacology.

Therefore, studying the modern problems of clinical pharmacology and developing solutions is of great importance for medical practice.

Main Part: Safety and side effects of drugs

The safety of drugs is one of the most important issues in clinical pharmacology. Any drug, while having a therapeutic effect, may also cause side effects. These effects can range from mild allergic reactions, dizziness, or nausea to serious disorders of liver, kidney, and heart function.

Side effects often occur due to incorrect dosage, ignoring individual patient characteristics, or taking multiple drugs simultaneously. This condition is more common in elderly patients and those with chronic diseases.



In addition, some drugs may accumulate in the body during long-term use and cause toxic effects. Therefore, in clinical practice, it is very important to correctly select drugs, accurately determine their dosage, and continuously monitor patients. This also indicates the necessity of developing pharmacovigilance systems.

Drug interactions

In clinical practice, patients are often prescribed several drugs at the same time. This leads to drug–drug interactions. As a result, the therapeutic effect of some drugs may increase, decrease, or completely disappear. At the same time, some combinations may increase toxicity and pose a risk to the patient's body.

Drug interactions occur through pharmacokinetic and pharmacodynamic mechanisms. In pharmacokinetic interactions, absorption, distribution, metabolism, or excretion of drugs changes. In pharmacodynamic interactions, drugs act on the same receptor or system, enhancing or reducing each other's effects. Especially when drugs metabolized in the liver and kidneys are used together, there is an increased risk of accumulation in the body.

Drug interactions are more common in elderly patients and those with chronic diseases, as they often use multiple medications at the same time. Therefore, in clinical pharmacology, it is very important to carefully select drug combinations, assess their interactions in advance, and continuously monitor the patient's condition.

Antibiotic resistance problem

Antibiotic resistance is one of the most serious global problems for clinical pharmacology and medicine as a whole. This condition occurs when microorganisms adapt to antibiotics and become resistant to their effects. As a result, drugs that were previously effective no longer provide sufficient results in treating infectious diseases.

The main causes of antibiotic resistance include improper and uncontrolled use of antibiotics, failure of patients to complete treatment courses, and unnecessary use of antibiotics for viral infections. In addition, the widespread use of antibiotics in agriculture and livestock also contributes to the spread of resistant bacteria.

As a result, even simple infections have become harder to treat, disease duration has increased, and the risk of complications has grown. Therefore, developing new antibiotics, rational use of existing drugs, and restricting the use of antibiotics without medical supervision are important tasks of clinical pharmacology.

Polypharmacy problem

Polypharmacy refers to the condition in which a patient is prescribed an excessive number of drugs at the same time, and it is especially common in elderly patients. This situation often occurs due to the presence of multiple chronic diseases and complicates the treatment process. Taking many drugs simultaneously increases drug interactions, raises the risk of side effects, and may reduce the effectiveness of some medications. In addition, excessive pharmacological load can negatively affect liver and kidney function.

Polypharmacy is not only a medical but also an economic problem, as it requires the use of many medications and long-term treatment. Therefore, in clinical pharmacology, it is important to follow rational pharmacotherapy principles and select only necessary and effective drugs. Careful selection of medications by doctors, reducing their number, and simplifying treatment are key ways to reduce polypharmacy.

Individual approach (personalized medicine)

The individual approach is one of the modern developing directions of clinical pharmacology, which means treatment based on the specific characteristics of each patient.



Every human body responds differently to drugs due to genetic, age, gender, body weight, metabolism rate, and overall health condition.

The same drug may be highly effective in one patient but less effective or even cause side effects in another. Therefore, standard treatment approaches are not always sufficient, and the need for individualized therapy is increasing.

Today, fields such as pharmacogenetics and pharmacogenomics are developing, enabling drug selection based on genetic characteristics of patients. This helps increase treatment effectiveness and reduce side effects.

Thus, the individual approach plays an important role in ensuring safe and effective treatment in clinical pharmacology and is considered one of the main directions of future medicine.

Development of new drugs and clinical trials

The development of new drugs is one of the most complex and time-consuming processes in clinical pharmacology. It begins with laboratory research and passes through several stages of clinical trials. At each stage, the safety, effectiveness, and effects of the drug on the body are carefully studied.

Clinical trials are usually conducted in three or four phases. Initially, safety is tested on a small group, and later effectiveness and side effects are evaluated in larger groups of patients. However, this process requires a lot of time, significant financial resources, and strict scientific control. Nevertheless, in some cases, clinical trials are not conducted fully or results are not properly evaluated. This may create risks when introducing drugs into clinical practice.

Therefore, it is very important to follow international standards, strictly control clinical research, and apply evidence-based approaches in drug development.

Counterfeit drugs and control problems

Counterfeit drugs are one of the serious problems of the healthcare system today. Such medicines may have incorrect composition, insufficient active ingredients, or none at all. As a result, they do not provide the expected therapeutic effect and may even harm the patient's health.

The spread of counterfeit drugs is often caused by weak control in the pharmaceutical market, illegal production, and distribution chains. The expansion of internet-based drug sales has further worsened this problem.

Taking such drugs can lead to disease progression, complications, and even life-threatening conditions. Therefore, it is very important to strengthen quality control of medicines, improve certification systems, and increase pharmaceutical awareness among the population. From the perspective of clinical pharmacology, reducing counterfeit drugs requires international cooperation and modernization of control systems using advanced technologies.

Modern technologies and digital pharmacology

In modern clinical pharmacology, the role of digital technologies and artificial intelligence is rapidly increasing. These technologies help in selecting drugs, calculating dosages, monitoring patient conditions, and evaluating treatment effectiveness more quickly and accurately. As a result, clinical decision-making becomes more scientifically based and less error-prone.

Artificial intelligence systems can analyze large amounts of medical data to predict disease progression, identify drug side effects, and detect high-risk patients. In addition, electronic medical records and digital platforms make it easier to monitor patient treatment processes.

Furthermore, technologies such as pharmacogenomics and big data are expanding the possibilities of personalized treatment, allowing selection of the most suitable drug and dose for each patient. This improves treatment effectiveness and reduces side effects. However, there are



also several challenges in using these technologies, including ensuring data security, maintaining confidentiality, possible errors due to incorrect algorithms, and the risk of reducing human control due to excessive reliance on technology.

Therefore, scientific approaches, strict control, and professional training are essential in the development of digital pharmacology. This field will contribute to making clinical pharmacology more effective and safer in the future.

Conclusion

In conclusion, clinical pharmacology plays a crucial role in modern medicine by ensuring the safe and effective use of medicinal products. The main challenges in this field include drug safety and side effects, drug–drug interactions, antibiotic resistance, polypharmacy, and the need for individualized treatment approaches.

In addition, the development of new drugs and their proper clinical testing remain complex and resource-demanding processes. The problem of counterfeit medicines further emphasizes the importance of strict quality control and strong regulatory systems.

Modern digital technologies, including artificial intelligence and big data, are opening new opportunities for improving drug selection, monitoring patient treatment, and increasing therapeutic effectiveness. However, these technologies also require careful regulation, data protection, and responsible use.

Overall, solving the current problems of clinical pharmacology requires scientific approaches, rational drug use, continuous monitoring, and the integration of modern technologies into healthcare systems.

References:

1. Katzung, B.G. *Basic & Clinical Pharmacology*. McGraw-Hill Education, 2021.
2. Goodman & Gilman. *The Pharmacological Basis of Therapeutics*. 13th Edition, McGraw-Hill, 2018.
3. Rang, H.P., Dale, M.M. *Pharmacology*. Elsevier, 2020.
4. Brunton, L.L., Hilal-Dandan, R., Knollmann, B.C. *Goodman & Gilman's Manual of Pharmacology and Therapeutics*. McGraw-Hill, 2019.
5. World Health Organization (WHO). *Medication Safety in Polypharmacy*. Geneva, 2019.
6. World Health Organization (WHO). *Global Action Plan on Antimicrobial Resistance*. Geneva, 2015.
7. U.S. Food and Drug Administration (FDA). *Drug Safety and Pharmacovigilance Guidelines*. 2022.
8. European Medicines Agency (EMA). *Guideline on Clinical Trials in Human Medicines*. 2021.
9. Silverman, R.B., Holladay, M.W. *The Organic Chemistry of Drug Design and Drug Action*. Academic Press, 2014.
10. DiPiro, J.T. *Pharmacotherapy: A Pathophysiologic Approach*. McGraw-Hill, 2020.